Blue Lake and CyanVac Publish Full Data from Open Label Phase 1 Clinical Study of COVID-19 Vaccine Candidate
Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, and its affiliate CyanVac LLC, today announced the publication in Science Advances of the full data set from the Phase 1 study of their intranasal COVID-19 vaccine candidate, CVXGA. Results of the study demonstrate CVXGA’s potential to be a safe, immunogenic and effective vaccine against COVID-19.
Blue Lake Biotechnology to Present Safety and Immunogenicity Data for its RSV Intranasal Vaccine Candidate at the 13th International RSV Symposium
Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, today announced that it will be presenting safety and immunogenicity data on BLB201, the company’s PIV5-based intranasal vaccine candidate, at the 13th International RSV Symposium, occurring March 12-15 in Iguazu, Brazil. The data to be presented includes analyses of the company’s completed Phase 1 study in adults as well as its ongoing Phase 1/2a study in children ages 8-59 months.
Blue Lake Biotechnology Reports Additional Promising Clinical Data from Ongoing Pediatric Clinical Study of Intranasal RSV Vaccine BLB201
Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, today announced positive data from a preliminary analysis of the first 63 infants and young children enrolled in the company’s Phase 1/2a clinical study of BLB201, an intranasal vaccine candidate against RSV.
Blue Lake and CyanVac Report Positive Phase 2a Data for Intranasal COVID-19 Vaccine Candidate
Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, and its affiliate CyanVac LLC, today reported data from a 227-participant Phase 2a clinical trial demonstrating the safety, tolerability, immunogenicity, and efficacy of CVXGA, the company’s intranasal vaccine candidate against COVID-19.
Blue Lake Biotechnology and CyanVac Announce Presentation on Intranasal Vaccine Candidates at the International Society for Vaccines Annual Congress
Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, and its affiliate CyanVac LLC, today announced the presentation of positive interim pediatric clinical data on BLB201, Blue Lake’s vaccine candidate against respiratory syncytial virus (RSV), at the 2024 ISV Annual Congress in Seoul, South Korea. The oral presentation also included discussion of Phase 1 clinical data on CVXGA, the companies’ clinical stage vaccine candidate against COVID-19.
Blue Lake Biotechnology Reports Positive Interim Clinical Data in Children for Its RSV Vaccine Candidate
Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, today announced preliminary data from the first two cohorts of a Phase 1/2a clinical trial studying BLB201, the company’s investigational vaccine against severe respiratory syncytial virus (RSV) disease. The data show that BLB201 is immunogenic and well tolerated, with no significant safety events reported to date following a single intranasal dose in RSV seropositive children 18-59 months of age. The ongoing trial is currently enrolling both RSV seropositive and RSV seronegative children as young as eight months of age.
Positive Phase 1 Data for Blue Lake Biotechnology’s Intranasal RSV Vaccine Published in Science Advances
Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing PIV5-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, announced the publication of positive Phase 1 clinical trial results of its intranasal RSV vaccine candidate BLB201 in Science Advances. Data generated during the first-in-human study of BLB201 showed that BLB201 was well-tolerated and stimulated RSV-specific antibody and cell mediated immune responses in adults ages 33 to 75 years following a single intranasal dose.
Blue Lake Biotechnology Presenting at Upcoming BioFuture and BIO Investor Forum Conferences
Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company enlisting the full breadth of the immune system to protect people from serious infectious diseases, today announced that management will be presenting and engaging in 1-1 meetings at the following upcoming investor conferences:
